A reference post rather than a discussion. Corrections are the point; I would rather this be right than mine. It is about the maintenance and discontinuation question, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
Extending the interval and reducing the dose are pharmacologically different. Reducing the dose lowers the whole exposure curve evenly; extending the interval keeps the peak and drops the trough. Since the appetite effect tracks the trough, interval extension tends to give you good days and bad days rather than a uniformly smaller effect, which most people find harder to live with.
The condition it depends on
The caveat that "maintenance dose" in the literature almost always means the top studied dose. Lower maintenance doses are widely used and thinly evidenced, which is worth knowing before you cite anything as established.
What I am not sure about
The question I want answered is whether there is a lowest maintenance dose with actual maintenance data behind it, or whether everything published sits at the top of the ladder. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
matt_MKE said:Extending the interval and reducing the dose are pharmacologically different.
No disagreement with matt_MKE. One condition attached. STEP 4 is the study that answers this and it is blunt. Participants who continued kept losing; participants switched to placebo regained about two thirds of what they had lost within a year, and the metabolic improvements faded with the weight. That is the same pattern as every other chronic-disease medication ever withdrawn, and it is an argument about the condition rather than about the drug.
matt_MKE said:Extending the interval and reducing the dose are pharmacologically different.
The regain framing needs pushing back on. Two thirds regained means one third did not, and the trial provided no ongoing support to either group. Treating regain as pharmacologically inevitable is as unsupported as treating maintenance as automatic.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsShort answer first, then the reasoning. One third of STEP 4 participants held most of their loss without the drug, and nobody has convincingly characterised who they are. That subgroup is the most interesting unanswered question in the field and it is routinely flattened into the two-thirds headline.
PharmacoVig_BOS said:STEP 4 is the study that answers this and it is blunt.
Second this.
Amazing transformation! Starting at 287 lbs, I'm now at 162 lbs after 18 months on semaglutide 2.4mg/wk. These photos show my progress at months 3, 6, 9, 12, 15, and 18. The body recomposition has been incredible — DEXA shows 23% body fat, down from 42%...